Search results
Mar 1, 2022 · KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Julie L. Gerberding, chief patient officer and executive vice president, population health and sustainability, will be retiring from Merck in May 2022.
Julie Louise Gerberding (born August 22, 1955) is an American infectious disease expert who was the first woman to serve as the director of the U.S. Centers for Disease Control and Prevention (CDC). As of May 2022, she is the CEO of the Foundation for the National Institutes of Health (FNIH).
Mar 1, 2022 · KENILWORTH, N.J.-- ( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Julie L. Gerberding, chief patient officer and executive...
Mar 1, 2022 · North Bethesda, MD, March 1, 2022 – The Foundation for the National Institutes of Health (FNIH) today announced the appointment of Dr. Julie Louise Gerberding, the 15th Director of the Centers for Disease Control and Prevention (CDC) and an executive at Merck & Co., Inc., as its next Chief Executive Officer. Dr.
View Julie Gerberding’s profile on LinkedIn, a professional community of 1 billion members. Dr. Julie Louise Gerberding is the CEO of the Foundation for the National Institutes of…
- Foundation for the National Institutes of Health
Mar 1, 2022 · KENILWORTH, N.J.-- ( BUSINESS WIRE) -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Julie L. Gerberding, chief patient officer and executive vice president, population health and sustainability, will be retiring from Merck in May 2022.
